TABLE 1

Clinical and biological parameters of 55 morbidly obese subjects

PhenotypeWhole populationLiver subset
n5539
F/M46/9 (83)31/8 (80)
Age (years)39.5 ± 1.4438.3 ± 1.63
BMI (kg/m2)47.9 ± 0.9347.8 ± 1.15
Glucose homeostasis
    Glucose (mmol/l)6.15 ± 0.296.24 ± 0.33
    Insulin (μU/ml)15.0 ± 1.2715.6 ± 1.44
    QUICKI0.320.32
Type 2 diabetes
    Glycemia >7 mmol/l or treatment12/55 (22)9/39 (23)
Lipids homeostasis
    Cholesterol (mmol/l)5.32 ± 0.125.37 ± 0.14
    HDL cholesterol (mmol/l)1.34 ± 0.061.33 ± 0.05
    Triglycerides (mmol/l)1.49 ± 0.111.47 ± 0.14
Adipokines
    Leptin (ng/ml)62.4 ± 3.8061.2 ± 4.13
    Adiponectin (μg/ml)7.01 ± 0.426.81 ± 0.51
Risk factors
    HDL <1.03 mmol/l (M), <1.29 mmol/l (F)25 (45)18 (46)
    Hypertension ≥130/85 mmHg24 (44)16 (41)
    Glucose ≥5.6 mmol/l25 (45)21 (54)
    Triglycerides ≥1.7 mmol/l17 (31)11 (28)
Inflammatory factors
    TNF-α (pg/ml)1.79 ± 0.071.87 ± 0.09
    Interleukin 6 (pg/ml)2.63 ± 0.182.74 ± 0.23
    High-sensitivity CRP (mg/dl)0.89 ± 0.090.91 ± 0.12
    Orosomucoid (g/l)0.99 ± 0.030.99 ± 0.03
    Serum amyloid A (μg/ml)31.5 ± 7.635.1 ± 10.1
Hepatic factors
    AST (IU/l)22.8 ± 1.5723.7 ± 1.98
    Alanine aminotransferase (IU/l)32.8 ± 3.7633.5 ± 4.40
    γGT (mg/dl)36.8 ± 2.9537.1 ± 3.31
  • Data are the means ± SE or n (%). Histology of hepatic biopsies was suitable for 39 individuals of the cohort, designated as the “liver subset.” No significant differences were observed between the two groups.